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Key Message: "This is the largest ever reported safety dataset on a general patient population presenting ABC 
treated with EVE plus EXE and included a sizeable elderly subset. This is also the first trial reporting the impact of 
BMI on safety. These data reinforce observations from the BOLERO-2 trial that the safety profile of everolimus plus 
exemestane was manageable; there were no new safety signals." 
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ABSTRACT  
Background: This European phase 3b, expanded-access multicenter trial evaluated the safety of EVE 
plus EXE in a patient population similar to BOLERO-2.  
Patients and methods: Postmenopausal women aged ≥18 years with hormone receptor-positive, human 
epidermal growth factor-receptor-2negative advanced breast cancer (ABC) recurring/progressing 
during/after prior non-steroidal aromatase inhibitors (NSAIs) were enrolled. Primary objective was safety 
of EVE plus EXE based on frequency of adverse events (AEs), and serious AEs (SAEs). Secondary 
objective was to evaluate AEs of grade 3/4 severity. 
Results: Median treatment duration was 5.1 months (95% CI, 4.8-5.6) for EVE and 5.3 months (95% CI, 
4.8-5.6) for EXE. Overall, 2131 patients were included in the analysis; 81.8% of patients experienced 
EVE- or EXE-related or EVE/EXE-related AEs (investigator assessed); 27.2% were of grade 3/4 severity. 
The most frequently reported non-hematologic AEs were (overall %, % EVE-related) stomatitis (52.8%; 
50.8%) and asthenia (22.8%; 14.6%). The most frequently reported hematologic AE were (overall %, % 
EVE-related) anemia (14.4%; 8.1%) and thrombocytopenia (5.9%; 4.6%). AE-related treatment 
discontinuations were higher in elderly (≥70 years) versus non-elderly patients (23.8% vs. 13.0%). The 
incidence of EVE-related AEs in both elderly and non-elderly patients appeared to be lower in first-line 
ABC versus later lines. The incidence of AEs (including stomatitis/pneumonitis) was independent of BMI 
status (post-hoc analysis). Overall, 8.5% of patients experienced at least one EVE-related SAE. Of the 
121 on-treatment deaths (5.7%), 66 (3.1%) deaths were due to disease progression and 46 (2.2%) due to 
AEs; 4 deaths were suspected to be EVE-related. 
Conclusions: This is the largest ever reported safety dataset on a general patient population presenting 
ABC treated with EVE plus EXE and included a sizeable elderly subset. Although the patients were more 
heavily pretreated, the safety profile of EVE plus EXE in BALLET was consistent with BOLERO-2.   
Clinical trial registration: EudraCT Number: 2012-000073-23 
Key words: advanced breast cancer, BMI, elderly, everolimus, hormone-receptor positive, stomatitis  
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Introduction 
Endocrine therapy (ET) is the treatment of choice for patients with HR+, human epidermal growth factor 
receptor 2-negative (HER2) advanced breast cancer (ABC) in both adjuvant and advanced settings [1-
5]. However, despite the effectiveness of ET many women experience disease progression, either de 
novo or acquired [6]. Hence, identification of effective targeted therapies, which may enhance or prolong 
endocrine sensitivity in these patients continues to be of clinical importance. Two different targeted 
agents, everolimus (a mammalian target of rapamycin [mTOR] inhibitor) and palbociclib (a cyclin-
dependent kinase 4/6 inhibitor) have each shown efficacy in this patient population [7, 8]. 
Extensive cross-talk between the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mTOR 
pathway and estrogen receptor signaling has been implicated as one of the key mechanisms of endocrine 
resistance [9-11]. Preclinical studies have shown that co-targeting both signaling pathways can 
synergistically inhibit tumor progression [9, 13, 14]. The pivotal BOLERO-2 trial showed that dual-
blockade with everolimus (EVE), an mTOR inhibitor, plus EXE more than doubled median progression 
free survival (PFS) vs EXE alone in patients with HR+, HER2 ABC recurring/progressing on prior NSAIs 
(7.8 months vs 3.2 months) [14]. The present European phase 3b, expanded-access multicenter trial, 
BALLET, further evaluated the safety of EVE plus EXE in patients with HR+, HER2 ABC 
recurring/progressing on prior NSAIs.  
 
Methods 
Patients 
Postmenopausal women aged ≥18 years with histologically/cytologically confirmed HR+ ABC 
unamenable to curative resection or radiotherapy, recurring or progressing on prior NSAIs were enrolled. 
NSAIs were not necessarily the last treatment prior to enrollment. There was no restriction on the number 
of prior lines of chemotherapy. Patients were excluded if they were HER2+ by local testing, were 
hypersensitive to mTOR inhibitors or EXE, had received radiotherapy within four weeks prior to 
enrollment, had symptomatic visceral disease, brain or central nervous system metastasis, or had 
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inadequate liver, renal, cardiac or bone marrow functions. Hormone replacement therapy had to be 
discontinued prior to enrollment. 
Written informed consent was obtained from all patients. The study was performed in accordance with the 
Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was approved by an 
independent ethics committee or institutional review board at each site. Dose modifications for specific 
treatment-emergent toxicities were advised in the protocol. 
Study design and treatment 
BALLET was a European, open-label, single-arm, multicenter phase 3b, expanded access trial (EudraCT 
Number: 2012-000073-23). Enrolled patients self-administered EVE on Day-1 and continued daily 
doses of EVE (either 2x5 mg or 1x10 mg) plus EXE (25 mg/day) in 28-day cycles. Study treatment 
continued until disease progression, intolerable toxicity, discontinuation from study due to other reasons, 
local reimbursement of EVE, or death. All patients also received best supportive care for pre-existing 
medical conditions or adverse events (AEs), as per standard local practice. Dose adjustments were 
allowed for AEs that were suspected to be related to EVE (additional information in Supplementary 
material). Permissible dose adjustments for EVE were 5 mg daily; 5 mg every other day. Relative dose 
intensity was defined as dose intensity (dosing unit/unit of time)/planned dose intensity. Permanent 
discontinuation involved discontinuation of either EVE or both EVE and EXE. Treatment once interrupted 
due to unacceptable toxicity was resumed only after recovery to grade ≤1 was achieved; reintroduction 
was at the initial/lower dose level according to study protocol. Patients were withdrawn from the study if 
the interruption was >28 days. 
Safety assessment 
The primary objective was to assess the safety of EVE plus EXE based on the frequency of AEs, serious 
AEs (SAEs) and number of laboratory abnormalities. The secondary objective was to evaluate AEs of 
grade 3 and 4 severity in routine clinical practice. Exploratory analysis included safety assessments in a 
subset of patients aged ≥70 years. Post hoc exploratory analyses evaluated the impact of body mass 
index (BMI) on the safety profile of EVE plus EXE. 
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Safety assessments included recording of all AEs and SAEs with their severity and relationship to study 
treatments, and deaths which occurred throughout the study and up to 28 days after the last treatment. 
The severity of AEs was graded according to National Cancer Institute Common Terminology Criteria for 
AEs v4.03 or on a scale of grade 14. Eastern Cooperative Oncology Group Performance Status (ECOG-
PS) was assessed at baseline and at each study visit. Patients who dropped out of the study but 
continued on EVE through reimbursement, were not followed up after their exit.   
Statistical analysis 
The study did not formally test any hypotheses; all analyses were descriptive. The safety analysis 
included all patients who received at least one dose of EVE or EXE and were evaluable at least one time 
point. No formal sample size calculation was performed; the estimated sample size of 2500 patients was 
chosen based on the expected average accrual rate and duration of the trial based on the expected date 
of reimbursement in each participating country. Kaplan-Meier method was used for the exploratory 
assessment of the median treatment durations in the full population and when the study treatment was 
administered in the first-line setting, after censoring patients who discontinued treatment due to 
reimbursement/switch to other EVE programs. 
 
Results 
Demographics 
Between 16-May-2012 and 31-December-2013, 2133 patients were enrolled at 267 centers in 14 
countries; 2131 patients were included in the safety analysis; two patients were excluded due to missing 
baseline safety assessment.  
The baseline demographic characteristics were comparable between the two treatment arms (Table 1; 
comparison with BOLERO-2 in Supplementary Table S1). The majority of patients (65.1%) received EVE 
plus EXE as a third-line of therapy or beyond in the advanced setting. Baseline patient characteristics of 
elderly patients were comparable to the non-elderly except for ECOG-PS 0/1/2 and less frequent prior 
chemotherapy in metastatic setting (additional information in Supplementary materials). 
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Treatment exposure  
The median duration of follow-up was 4.6 months (range: <1–24.2 months). The median treatment 
duration was 3.7 months each for both EVE and EXE and appeared to be longer in patients who received 
EVE plus EXE as first-line therapy (4.4 months for EVE and 4.6 months for EXE). After censoring patients 
who discontinued treatment due to reimbursement/switch to other everolimus programs the median 
treatment duration was 5.1 months for EVE and 5.3 months for EXE and as first-line therapy, 6.1 months 
for both EVE and EXE; Figure 1A). Most common reasons for treatment discontinuation were disease 
progression (36.8%), local reimbursement of EVE (33.4%) and AEs (15.8%). Those patients who dropped 
out of the study continued on reimbursed EVE, however, the study did not plan to follow-up on them until 
treatment discontinuation. The overall median RDI was 0.98 (range: 0.11.1) for EVE and 1.0 (range: 
0.41.0) for EXE.  
In the elderly subset, the median duration of exposure was 3.2 months for EVE and 3.5 months for EXE. 
After censoring elderly patients who discontinued treatment due to reimbursement or crossover to other 
EVE programs, median duration of exposure was 3.8 months for EVE and 4.1 months for EXE, which was 
shorter compared to that in non-elderly patients, 5.0 months for EVE and 5.2 months for EXE. The 
median RDI for EVE was lower (0.95) in the elderly in comparison to non-elderly patients (1.0). 
Dose interruptions, reductions and discontinuations 
Overall, 29.6% and 1.2% of patients required dose reduction for EVE and EXE, respectively, the most 
common reasons being AEs (14.1% vs 0%) and medical decision (10.3% vs 0.1%). Dose interruptions for 
EVE and EXE were required for 55.9% and 19.3% of patients, respectively. More than half (52.3%) of the 
patients who needed a dose interruption were able to restart EVE at full dose. The median duration of 
dose interruption was 17 days. The median time to first dose modification was 32 days for EVE and 45 
days for EXE. Permanent discontinuation of EVE was avoided through dose reduction in most patients; 
only 18.1% of these patients were unable to continue therapy thereafter for AEs. On the other hand, 
15.1% of patients who never had a dose reduction stopped EVE permanently due to AEs. 
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Dose reductions and interruptions were higher in the elderly compared to non-elderly patients (37.7% and 
60.5%, respectively vs. 26.7 % and 54.2%, respectively) (Supplementary Table S2). The most common 
AEs requiring dose adjustment in the elderly versus non-elderly patients were stomatitis (27.9% vs. 
21.2%), asthenia (8.9% vs. 3.6%), anaemia (6.2% vs. 3.1%) and non-infectious pneumonitis (NIP, 5.9% 
vs. 4.8%), respectively. The median time to first dose modification was 30 days in the elderly and 33 days 
in non-elderly patients.  
AEs led to permanent treatment discontinuation in 17.1% of patients (grade 3/4, 10%); the majority of 
these occurred within the first three months from treatment initiation. The most frequently reported AEs 
that led to permanent treatment discontinuation were (all grade; grade 3/4) NIP (2.4%; 0.8%), stomatitis 
(1.9%; 1.0%), asthenia (1.5%; 0.9%), and dyspnea (1.1%; 0.5%). AE-related treatment discontinuations 
were reported for 18.9% of the elderly versus 10.6% of non-elderly patients.  
AE-related discontinuations were higher in the elderly versus non-elderly patients (23.8% vs. 13.0%). In 
the elderly, the most frequently reported AEs leading to permanent discontinuation of EVE or EVE plus 
EXE in the elderly versus non-elderly patients were stomatitis (3.9% vs. 1.2%) and NIP (3.4% vs. 2%). 
Safety 
Overall, 94.7% of patients experienced at least one any grade AE and 42.7% of patients experienced at 
least one grade 3/4 AE irrespective of relationship to EVE. Of these, 81.8% and 15.1% of AEs were 
assessed by the investigators to be EVE- or EXE-related, respectively; 27.2% and 1.6%, respectively 
were of grade 3/4 severity. The most frequently reported nonhematologic (all grade) AEs were stomatitis 
(52.8%; 50.8% were EVE-related), and asthenia (22.8%; 14.6% were EVE-related). Anemia (14.4%; 8.1% 
were EVE-related), and thrombocytopenia (5.9%; 4.6% were EVE-related) were the most frequently 
reported hematologic AEs (Table 2). The majority of EVE-related AEs were of grade 1/2 severity; the 
incidences of grade 3 or 4 stomatitis or NIP were low (Table 2; comparison with BOLERO-2 in 
Supplementary Table S3).  
In the elderly subset, 95.2% of patients experienced at least one AE. The most common any grade AEs in 
elderly versus non-elderly patients were stomatitis (55.5% vs. 51.9%), asthenia (28.5% vs. 20.7%) and 
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decreased appetite (22.4% vs. 13.7%); the most frequent grade 3 or 4 AEs were stomatitis (12.3% vs. 
8.3%), asthenia (5.7% vs. 2.9%) and hyperglycaemia (4.6% vs. 2.3%). NIP was reported in 11.2% of 
elderly versus 8.9% of non-elderly patients (Supplementary Table S4). 
Post hoc analysis showed that the incidences of any grade AEs following EVE, including grade 3/4 AEs of 
special interest like stomatitis (range: 5.4-9.8%), NIP (range: 1.3-2.7%), asthenia/fatigue (range: 4.1-
8.1%) were independent of the patients’ BMI status (Supplementary Table S5). 
The median time to onset for stomatitis events and NIP events were 29 days (range: 1396) and 87 days 
(range: 1231), respectively (Figure 1B). The median duration of a stomatitis event was 16 days and of a 
NIP event was 19 days. The incidence of EVE-related AEs appeared to be lower in the first-line setting for 
ABC vs later lines, with a numerically lower incidence observed for stomatitis (45.6% vs 51.4%), rash 
(11.4% vs 15.1%), asthenia (10.9% vs 15.1%) and diarrhea (9.1% vs 10.7%). Grade 3/4 stomatitis (7.7% 
vs 9.4%), diarrhea (0.5% vs 0.9%), rash (0.5% vs 1.0%) and NIP (0.9% vs 1.9%) were also reported less 
frequently in the first-line setting vs later lines.  
Overall, 21.2% of patients experienced at least one SAE regardless of the relationship to any study 
treatment [Supplementary Table S6]; 8.5% of patients experienced at least one EVE-related SAE. The 
most frequent SAEs were dyspnea (2.4%), NIP (2.2%), pyrexia (1.6%), anemia (1.3%) and pleural 
effusion (1.2%). Treatment-related SAEs were reported in 10.3% of the elderly versus 7.8% of non-elderly 
patients. 
Survival and follow-up status 
At the time of analysis, 121 (5.7%) on-treatment deaths were recorded in the full study population. Deaths 
were attributable to disease progression (66 [3.1%]), AEs (46 [2.2%]) and unknown reasons (9 [0.4%]). 
On-treatment deaths were reported in 39 (6.9%) elderly patients; the deaths were attributable to 
progressive disease (18 [3.2%]), AEs (16 [2.8%]) (additional data in Supplementary Table S7), and others 
reasons (5 [0.9%]). AEs suspected to be EVE-related leading to death were reported in 4 patients: NIP (2 
patients), general physical health deterioration, and cardio-respiratory arrest (1 patient each). .  
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Overall, 69.2% of patients received at least one anti-neoplastic medication since study treatment 
discontinuation [Supplementary Table S8].  
 
Discussion  
To our knowledge, this is the largest ever reported safety dataset on a general patient population 
presenting HR+, HER2 ABC progressing on prior NSAIs, treated with EVE plus EXE. Further, the 
exploratory safety analysis in the elderly subset in BALLET is by far the largest safety dataset in this age 
group.  
Overall, the patient population in BALLET was more heavily pretreated compared with BOLERO-2 [14]. 
Patients in BALLET were treated in later lines (65% vs 54% in BOLERO-2 in third-line and beyond) [14], 
and with more prior chemotherapy (60% vs 26% in BOLERO-2; 20.8% of patients in BALLET received ≥3 
lines of chemotherapy in the metastatic setting) because the trial did not impose limitations in term of 
number of prior chemotherapy [14]. This may be one of the reasons why fewer patients in BALLET 
received any post-treatment therapy than those in BOLERO-2 (69.2% vs 84%) [15]. The short follow-up 
period could be another reason for this observation. 
The incidence of stomatitis (52.8% vs 59%) and NIP (9.5% vs 16%) were lower in BALLET compared with 
BOLERO-2 [14]; this difference may be attributed to the shorter median follow-up in BALLET compared 
with BOLERO-2 (4.6 months vs 17.7 months). This could be because long-term safety profile of EVE 
could not be evaluated in those patients in BALLET who dropped out of the study but continued on EVE 
under reimbursement. Another plausible reason for this difference could be the variability across study 
sites in the reporting of low-grade stomatitis. Consistent with BOLERO-2, the most common AEs leading 
to treatment discontinuation in BALLET were NIP (2.4% vs 5.6% in BOLERO-2) and stomatitis (1.9% vs 
2.7% in BOLERO-2) [14]. In BALLET, fewer treatment-emergent AEs were reported in the first-line setting 
compared with later lines.  
Median duration of treatment with EVE in BALLET was lower compared with BOLERO-2 (16 weeks vs 
23.9 weeks), even though the median RDI was higher [14]. This may suggest an improvement in 
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treatment optimization. Indeed, fewer patients in BALLET discontinued study drug due to AEs (17.1% 
compared with patients in BOLERO-2 [26.3%]) [14] and clinicians preferred a temporary treatment 
interruption over permanently discontinuation.  
The trends in the safety profile of EVE plus EXE in  elderly patients in BALLET were consistent with the 
≥70 years subset (n=121) in the BOLERO-2 trial [16]. The median duration of exposure to EVE and EXE 
was shorter and the corresponding RDIs were lower in the elderly compared to non-elderly patients. Dose 
reductions, interruptions and AE-related study treatment discontinuations, grade 3/4 AEs, treatment-
related SAEs and on-treatment deaths were higher in the elderly compared with non-elderly patients.  
BALLET is also the first trial reporting the impact of BMI on safety. Post hoc analysis showed that the 
incidence of AEs was independent of BMI status. This observation bears clinical implications as it 
appears that patients with lower BMI do not require a lower EVE starting dose.  
Given that globally relevant clinical practice guidelines for breast cancer recommend EVE plus AIs 
including EXE as a treatment option for patients with HR+, HER2 ABC recurring or progressing on/after 
prior NSAIs [1, 17], these data add safety information to the clinical relevance of the efficacy data. Given 
the early incidence of AE and dose interruption/modification observed in BALLET, close follow-up in the 
first months of therapy is indicated. We recommend a first visit 2 weeks after starting EVE (only one 
month in BALLET) in order to further reduce EVE-related discontinuation rate. 
The rate of study discontinuation due to EVE reimbursement (33.4%) was high. Although these patients 
continued on reimbursed EVE, they could not be followed-up until definitive treatment discontinuation. 
This might have influenced the long-term safety profile of the study treatments and treatment duration. An 
exploratory analysis of treatment duration censoring patients who discontinued treatment due to 
reimbursement showed the median duration of treatment to be 5.1 months and 5.3 months for EVE and 
EXE, respectively but a similar analysis for safety was not feasible from a statistical point of view due to 
lack of sufficient power. Despite these limitations, the inherent strength of BALLET lies in the sizeable 
study population that was evaluated to provide meaningful safety data that support the utilization of the 
dual inhibition strategy with EVE plus EXE in this patient population.  
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Given that BALLET was an expanded access program, the methodology did not allow for the assessment 
of PFS; however, given that the duration of exposure is surrogate marker for PFS, this has allowed cross-
trial comparisons, in particular with the BOLERO-2 trial. As is inherent to expanded access trial designs, 
this design of BALLET allowed for inclusion of patients unrestricted by the demographic profile of the 
BOLERO-2 patient population. This allowed for meaningful evaluation of the safety profile of EVE plus 
EXE in an a larger patient population that mimicked the real-world setting.    
In conclusion, this is the largest ever reported safety dataset on a general patient population including a 
sizeable elderly subset, in patients with HR+, HER2 ABC progressing on prior NSAIs. The safety profile 
of EVE plus EXE in BALLET is consistent with previous observations from BOLERO-2. There were no 
new safety signals. Diligent monitoring, proactive communication, early detection and implementation of 
appropriate AE-management strategies can ensure better treatment optimization.  
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Figures Legends 
Figure 1A Kaplan Meier curve for time to treatment discontinuation after censoring patients 
who discontinued treatment due to reimbursement or natural death (Safety set) 
Figure 1B Median time to onset for stomatitis events and noninfectious pneumonitis (NIP) 
events (Safety set) 
  
 at K
U
 Leuven U
niversity Library on July 5, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
100
80
60
40
20
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Time (months)
P
ro
ba
bi
lit
y 
of
 e
ve
nt
 (%
)
Everolimus (795/2129): 5.1 months (95% CI 4.8–5.6)
Exemestane (795/2128): 5.3 months (95% CI 4.8–5.6)
Censoring times
Everolimus
Exemestane
 at K
U
 Leuven U
niversity Library on July 5, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
100
80
60
40
20
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Time (months)
P
ro
ba
bi
lit
y 
of
 e
ve
nt
 (%
)
 Total Censored Events
Stomatitis 2131 1005 1126
NIP 2131 1928 203
Censored
Stomatitis
NIP
Stomatitis
NIP
 at K
U
 Leuven U
niversity Library on July 5, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Table 1 Baseline and treatment characteristics (including data for prior therapies by number of 
prior chemotherapy lines) (Full analysis set) 
Characteristic N = 2133 
Median age (range), years 63.0 (28-90) 
Age categories 
< 70 years, n (%) 
≥ 70 years, n (%) 
 
1570 (73.6%) 
563 (26.4%) 
Median BMI (range) 25.7 (14.69-54.57) 
Race, n (%) 
Caucasian 
Black 
Asian 
Native American 
Others 
 
2100 (98.5%) 
5 (0.2%) 
1 (0.0%) 
1 (0.0%) 
26 (1.2%) 
Ethnicity, n (%) 
Hispanic/Latino 
Indian 
Other 
 
314 (14.7%) 
1 (0.0%) 
1818 (85.2%) 
ECOG PS 
0 
1 
2 
Missing 
 
1383 (64.8%) 
670 (31.4%) 
56 (2.6%) 
24 (1.1%) 
Characteristic N = 2131 
Current disease status, n (%) 
Metastatic 
Locally advanced 
 
1762 (82.7%) 
369 (17.3%) 
Metastatic site, n (%) 
Bone only 
Visceral 
Visceral only 
Bone and visceral 
Others 
 
543 (25.5%) 
1277 (59.9%) 
208 (9.8%) 
924 (43.4%) 
775 (36.4%) 
Number of metastatic site, n (%) 
≥5 
4 
3 
2 
1 
 
469 (22.0%) 
281 (13.2%) 
437 (20.5%) 
509 (23.9%) 
435 (20.4%) 
Median time to first diagnosis (range), days 2908 (-16218- -76) 
Key comorbidities, n (%) 
Vascular 
Metabolic and nutritional 
Musculoskeletal and connective tissue 
Psychiatric 
Gastrointestinal 
 
808 (37.9%) 
676 (31.7%) 
599 (28.1%) 
410 (19.2%) 
259 (12.2%) 
Number of lines of prior antineoplastic 
therapy in metastatic setting, n (%) 
None (adjuvant therapy only) 
1 
2 
3 
4 
≥5 
 
 
222 (10.4) 
518 (24.3%) 
483 (22.7%) 
345 (16.2%) 
209 (9.8%) 
350 (16.4%) 
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Key prior antineoplastic therapies, n (%) 
Aromatase inhibitors 
Anti-estrogens 
Chemotherapy in metastatic setting 
Immunosuppressant 
Monoclonal antibodies 
2131 (100%) 
2122 (99.6%) 
1579 (74.1%) 
1284 (60.3%) 
564 (26.5%) 
272 (12.8%) 
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Table 2 Adverse events of ≥10% incidence in either treatment group or grade 3, 4 AEs of  
≥0.5% incidence in either treatment group (Safety set) 
Adverse event (N = 2131),  
n (%) 
All grades Grade 3 Grade 4 
Stomatitis 1126 (52.8%) 198 (9.3%) 2 (0.1%) 
Asthenia 485 (22.8%) 75 (3.5%)     2 (0.1%) 
Diarrhea 359 (16.8%) 26 (1.2%)     1 (0.0%) 
Rash 351 (16.5%) 20 (0.9%)              0 
Decreased appetite 341 (16.0%) 24 (1.1%)             0 
Anemia 306 (14.4%) 0 0 
Pyrexia 299 (14.0%) 7 (0.3%)     3 (0.1%) 
Fatigue 298 (14.0%) 26 (1.2%)     1 (0.0%) 
Hyperglycemia 265 (12.4%) 60 (2.8%)     3 (0.1%) 
Peripheral edema 259 (12.2%) 13 (0.6%)              0 
Nausea 255 (12.0%) 13 (0.6%)             0 
Cough 254 (11.9%) 8 (0.4%)              0 
Dyspnea 220 (10.3%) 39 (1.8%)     4 (0.2%) 
Decreased weight 217 (10.2%) 2 (0.1%)             0 
Hypercholesterolemia 216 (10.1%) 1 (0.0%) 1 (0.0%) 
NIP 203 (9.5%) 35 (1.6%) 6 (0.3%) 
NIP, noninfectious pneumonitis 
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